BioWorld - Saturday, January 25, 2020

Deals and M&A
%{topic} RSS Feed RSS

Deal-handshake-wire-frame.png

Masimo to buy Nanthealth’s connected care business, provides estimates for 2020 guidance

January 14, 2020
By Liz Hollis
No Comments
Irvine, Calif.-based Masimo Corp. has agreed to buy the connected care assets of Nanthealth Inc., of Culver City, Calif., for a $47.25 million up-front cash payment. In addition, Masimo provided estimates for its full-year 2020 financial guidance, saying product revenue will increase to $1.035 billion, which reflects reported growth of 10.6% to 10.9%. The transaction is expected to close in the first quarter of the year, subject to customary closing conditions. In addition, Masimo expects to fund the acquisition with existing cash on hand.
Read More
Deal partnership chain link
Up to $1.1B in milestones

Morphosys banks $750M up front plus $150M in stock sale as Incyte swoops in on tafasitamab

January 13, 2020
By Cormac Sheridan
No Comments
Ten days after its JAK1 inhibitor, itacitinib, failed a phase III trial in acute graft-vs.-host-disease (GVHD), Incyte Corp. has finalized a deal that could provide an alternative growth path. It is paying Morphosys AG $750 million up front, investing $150 million in its stock and is on the hook for up to $1.1 billion in milestones for a 50% interest in U.S. rights to the CD19-targeting antibody tafasitamab (MOR-208) and for 100% of the rights in all other territories.
Read More
1-10-sebacia.png

Sebacia names CEO, picks up Sienna assets

January 10, 2020
By Liz Hollis
No Comments
Duluth, Ga.-based Sebacia Inc., which is focused on dermatology and aesthetics, has introduced its new CEO and reported the acquisition of all assets related to Sienna Biopharmaceuticals Inc.'s silver photoparticle technology, which is being reviewed by the FDA for light hair removal.
Read More

Popular Stories

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe